Skip to main content

MorphoSys AG (MOR)

NASDAQ: MOR · IEX Real-Time Price · USD
11.26 -0.43 (-3.68%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap1.54B
Revenue (ttm)143.47M
Net Income (ttm)-102.58M
Shares Out136.50M
EPS (ttm)-0.91
PE Ration/a
Forward PE322.58
Ex-Dividend Daten/a
Previous Close11.69
Day's Range11.22 - 11.54
52-Week Range10.86 - 30.75
Price Target23.40 (+107.8%)
Est. Earnings DateNov 10, 2021

About MOR

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; G...

IPO DateMar 9, 1999
CEOSimon Moroney
Stock ExchangeNASDAQ
Ticker SymbolMOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for MorphoSys stock is "Buy." The 12-month stock price forecast is 23.40, which is an increase of 107.82% from the latest price.

Price Target
(107.82% upside)
Analyst Consensus: Buy


MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzarta...

2 days ago - Accesswire

MorphoSys AG Unsponsored ADR (MOR) Upgraded to Strong Buy: Here's What You Should Know

MorphoSys AG Unsponsored ADR (MOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 week ago - Zacks Investment Research

MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food a...

1 week ago - Accesswire

Real Estate ETFs at All-Time Highs: Here's Why

The U.S. real estate sector is in the pink this year. Rising inflation, uptick in home prices, booming cloud business and attractive yield

1 month ago - Zacks Investment Research

Biotech Takeovers Moved at Snail's Pace in 2nd Quarter

Clovis Oncology Inc. ( CLVS , Financial) and Denali Therapeutics Inc. ( DNLI , Financial) are among the most likely biotechs to be acquired, according to industry publications. Denali, by far, would be ...

1 month ago - GuruFocus

Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug

Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.

Other symbols:INCY
1 month ago - Zacks Investment Research

Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell ly...

Other symbols:INCY
1 month ago - Benzinga

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenali...

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Mi...

1 month ago - Accesswire

MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Grea...

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a...

2 months ago - Accesswire

MorphoSys AG Reports Second Quarter and First Half 2021 Results

- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and cl...

2 months ago - Accesswire

MorphoSys Stock Falls After Trimming Upper End Of 2021 Revenue Outlook

MorphoSys AG (NASDAQ: MOR) expects group revenues of €155 million to €180 million (previously: €150 to € 200 million, provided on March 15 and reiterated on May 5, 2021).  The updated revenue guidance p...

2 months ago - Benzinga

MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announce...

2 months ago - Accesswire

Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, wi...

3 months ago - Accesswire

MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a res...

3 months ago - Accesswire

MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hemat...

Company Announces Successful Completion of Tender Offer   Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:...

3 months ago - Accesswire

MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitr...

3 months ago - Accesswire

MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatmen...

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is base...

Other symbols:INCY
3 months ago - Accesswire

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constella...

4 months ago - Accesswire

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalid...

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a ...

Other symbols:INCY
4 months ago - Accesswire

Why MorphoSys Stock Sank This Week

Investors weren't happy about the drugmaker's wheeling and dealing.

4 months ago - The Motley Fool

Constellation (CNST) Surges on Takeover Deal With MorphoSys

Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.

4 months ago - Zacks Investment Research

SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.

NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Co...

4 months ago - PRNewsWire

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to...

Other symbols:RPRX
4 months ago - Benzinga

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Phar...

4 months ago - Accesswire

MorphoSys to Acquire Constellation Pharmaceuticals

PLANEGG/MUNICH, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) (“Constellation”) today announced...

4 months ago - Business Wire